Electromedical Technologies Announces Financial and Operational Highlights for the Three Months Ended March 31, 2022


SCOTTSDALE, AZ -- May 24, 2022 -- InvestorsHub NewsWire -- Electromedical Technologies, Inc. (OTCQB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.

"We continue to drive strong growth on the topline, which is critical given the inherent scalability of our model and our capacity to expand with strong margins," noted Matthew Wolfson, Founder and CEO of Electromedical. "Our flagship device, the WellnessPro plus, has helped thousands upon thousands of people over the past 15 years get their lives back and enjoy a pain free life without the use of opioids. These trends are picking up in our core business and our focus on investing in marketing and sales personnel and initiatives continues to pay off and provide a strong outlook ahead as we move closer toward the commercial launch of our next generation product line."

Financial Performance Highlights for the Three Months Ended Mar 31, 2022

  • Net Sales increased 33% year over year to $221,894
  • Gross Profit increased 24% year over year
  • Gross Margin decreased from 75% to 70%, impacted by additional freight costs to expedite inventory delivery
  • Overall Net Loss dropped 55% year over year to $1.1 million

Operational Highlights for the Three Months Ended Mar 31, 2022

  • Continued investments in Marketing and Sales initiatives.
  • Hired Director of Business and Sales Development with deep industry track record and experience.
  • Made strong R&D gains in development of new product line targeting October 2022 full commercial launch.

Management sees the Company's continued strides in topline growth as further reinforcement for its strategic decision to invest heavily in sales and marketing, both in terms of personnel and other key strategies. In particular, the Company's decision to hire a top industry veteran with a long track record of success, David Orn, as its new Director of Business and Sales Development has been important in driving further topline expansion.

Orn added, "My goal for this year is to onboard  100 active independent medical sales reps, selling the Wellness Pro plus every month."

Wolfson added, "Q1 was a strong start to an exciting year with bold steps ahead. I'm proud of our team and grateful for the new talent we have been adding as we scale our operations, and I look forward to sharing more with our stakeholders as we push past new milestones in the months ahead."


About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. 

For more information, please visit www.electromedtech.com.

Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.


Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


Corporate Contact:
Electromedical Technologies, Inc.
Tel: 1.888.880.7888
Email: ir@electromedtech.com














March 31, 2022


December 31, 2021








Current assets:







Cash and cash equivalents







Accounts receivable














Prepaid expenses and other current assets







Total current assets














Property and equipment, net







Total assets




























Current liabilities:







Accounts payable







Credit cards payable







Accrued expenses and other current liabilities







Customer deposits







Convertible promissory notes, net of discount of $492,877 and $723,166, respectively







Related party notes payable







Long term debt, current portion







Total current liabilities














Long-term liabilities:







Bank debt, net of current portion







Government debt, net of current portion







Other liabilities







Total liabilities














Commitments and contingencies














Stockholders' deficit







Series A Preferred Stock, $.00001 par value, 1,000,000 shares authorized and 500,000 outstanding







Series B Preferred Stock, $.00001 par value, 1 share authorized and 0 outstanding







Common stock, $.00001 par value, 500,000,000 and 250,000,000 shares authorized; 104,955,567 and 87,725,842 shares outstanding at March 31, 2022 and December 31, 2021, respectively







Additional paid-in-capital







Accumulated deficit







Total stockholders' deficit







Total liabilities and stockholders' deficit

























Net sales














Cost of sales














Gross profit














Selling, general and administrative expenses














Loss from operations














Other income (expense)







Interest expense







Change in fair market value of derivative liabilities







Other income (expense)







Loss on extinguishment of debt







Forgiveness of debt







Total other expense














Net loss







Deemed dividend related to warrant resets







Net loss attributable to common stockholders














Weighted average shares outstanding - basic and diluted







Weighted average loss per share - basic and diluted

























Cash flows from operating activities:







Net loss







Adjustments to reconcile net loss to net cash used in operating activities:







Stock-based compensation expense







Depreciation and amortization







Forgiveness of debt







Loss on extinguishment of debt







Amortization of debt discount and day one derivative loss and warrant expense







Change in fair value of derivative liabilities- convertible promissory notes







Change in operating assets and liabilities:







Accounts receivable














Prepaid expenses and other current assets







Other assets







Accounts payable







Credit cards payable







Accrued expenses and other current liabilities







Customer deposits







Other liabilities







Net cash used in operating activities














Cash flows from financing activities:







Repayments on bank debt







Related party notes payable-net







Issuance of convertible promissory notes







Repayments on convertible promissory notes







Repayments on notes payable







Issuance of common stock for cash - net







Net cash provided by financing activities














Net (decrease) increase in cash and cash equivalents














Cash and cash equivalents, beginning of period














Cash and cash equivalents, end of period














Supplemental disclosures of cash flow information:







Cash paid during the period for:














Income taxes














Non-cash investing and financing activities:














January 1,2022 adoption of ASU2020-06







Warrants, common stock and beneficial conversion feature issued in conjunction with convertible promissory notes







Derivative liabilities issued in conjunction with convertible promissory notes







Conversion of convertible promissory notes, derivative liabilities and accrued interest into shares of common stock








ElectroMedical Technolog... (QB) (USOTC:EMED)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more ElectroMedical Technolog... (QB) Charts.
ElectroMedical Technolog... (QB) (USOTC:EMED)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more ElectroMedical Technolog... (QB) Charts.